Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus Publisher Pubmed



Tavakolpour S1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Dermatologic Therapy Published:2018


Abstract

Pemphigus is a rare, but life-threatening autoimmune disease with a high rate of morbidity and mortality, if left untreated. After the development of corticosteroid therapy in the 1950s, the death rate for pemphigus has significantly decreased. However, finding more potent therapeutic options for refractory patients has remained a controversial topic. In the recent years, rituximab has increasingly been used for the treatment of refractory pemphigus, but some patients do not well-respond. In addition, there is a paucity of evidence to support the risk of diseases exacerbation after rituximab therapy. In this study, as a JAK1 and JAK3 inhibitor, tofacitinib has been proposed for the treatment of refractory pemphigus patients. © 2018 Wiley Periodicals, Inc.
Related Docs
View other Related Docs
1. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
2. Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, But Not Chronic Patients With Inactive Disease Compared to Healthy Controls, Dermatology Practical and Conceptual (2021)
3. The Dual Nature of Retinoic Acid in Pemphigus and Its Therapeutic Potential: Special Focus on All-Trans Retinoic Acid, International Immunopharmacology (2016)
4. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
5. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
6. Towards Personalized Medicine for Patients With Autoimmune Diseases: Opportunities and Challenges, Immunology Letters (2017)
7. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
8. What Is Novel in the Clinical Management of Pemphigus Vulgaris?, Expert Review of Clinical Pharmacology (2024)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (25)
Hamid Reza Mahmoodi (20)
Other Related Docs
9. The Possible Role of Interleukin-35 and Its Therapeutic Potential in Pemphigus, International Immunopharmacology (2017)
10. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
11. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)
12. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
13. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
14. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
15. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
16. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
17. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
18. The Elevated Level of Osteopontin in Patients With Pemphigus Vulgaris: A Cytokine-Like Protein With a Therapeutic Potential, Dermatologic Therapy (2019)
19. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
20. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)
21. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
22. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
23. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
24. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
25. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)
26. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
27. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
28. Anti-Desmoglein-1 Levels As Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab, Dermatologic Therapy (2018)
29. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)